Does daptomycin cause elevation of liver enzymes (ALT, AST, bilirubin)?

Does Daptomycin Cause Liver Function Test Elevation?

Yes, daptomycin can cause liver function test elevations, though this is uncommon. According to the FDA label, abnormal liver function tests occurred in ≥2% of adult patients with complicated skin and skin structure infections receiving daptomycin, and specific elevations including increased alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood alkaline phosphatase, and jaundice were reported in <1% of patients 1.

Clinical Significance and Frequency

The hepatotoxicity associated with daptomycin is rare but documented. The FDA labeling lists "abnormal liver function tests" as one of the common adverse reactions, along with specific transaminase elevations 1. In clinical practice:

• Transaminase elevations (ALT/AST) are the most commonly reported hepatic abnormality
• Hyperbilirubinemia has been documented in case reports, though less frequently
• Most cases are asymptomatic and detected through routine monitoring

Key Clinical Features

Multiple case reports demonstrate that daptomycin-induced liver injury typically presents with:

• Asymptomatic transaminitis without concurrent multiorgan dysfunction 2, 3
• Elevations can occur without concurrent creatine phosphokinase (CPK) elevation, distinguishing it from the more commonly recognized daptomycin-associated rhabdomyolysis 2, 4, 5
• Resolution typically occurs after discontinuation of daptomycin 2, 4, 3
• Risk appears higher with high-dose and long-term therapy 4

Important Clinical Distinctions

Daptomycin-induced hepatotoxicity can occur independently of rhabdomyolysis. While daptomycin is more commonly associated with CPK elevations and muscle toxicity, several case reports document isolated liver injury without CK abnormalities 2, 4, 5. This is a critical pitfall—clinicians monitoring only CPK levels may miss hepatotoxicity.

One case described acute liver failure requiring daptomycin discontinuation in a patient treated for MRSA endocarditis for 3 weeks, with complete resolution after drug withdrawal 4. Another documented both renal and hepatic toxicity without rhabdomyolysis or CK elevation 5.

Monitoring Recommendations

Based on the documented cases and FDA labeling:

• Baseline liver function tests should be obtained before initiating daptomycin
• Weekly monitoring of ALT, AST, and bilirubin is reasonable, especially for:
  • Patients requiring long-term therapy (>2 weeks)
  • High-dose regimens (≥6 mg/kg)
  • Patients with pre-existing liver disease
• Monitor concurrently with CPK levels, as these are independent toxicities 4, 5

Management Algorithm

When liver enzyme elevations occur during daptomycin therapy:

1. Rule out alternative etiologies: viral hepatitis, biliary obstruction, other hepatotoxic medications, sepsis-related cholestasis
2. If ALT/AST >3× baseline or >300 U/L: Repeat testing within 2-5 days and consider interrupting daptomycin 6
3. If ALT/AST >5× baseline or >500 U/L: Discontinue daptomycin, repeat labs within 2-5 days, initiate workup for competing etiologies 6
4. If transaminase elevation with bilirubin ≥2× baseline: Discontinue daptomycin immediately—this suggests more severe hepatocellular injury 6

Clinical Context

A retrospective cohort analysis of 614 admissions receiving daptomycin found no additional cases of probable or definite drug-induced liver injury beyond isolated case reports, suggesting the incidence is genuinely low 3. However, the documented cases demonstrate that when hepatotoxicity occurs, it can be severe and requires prompt recognition and drug discontinuation.

The key clinical takeaway: While uncommon, daptomycin-induced hepatotoxicity is real, can occur without rhabdomyolysis, and requires monitoring beyond just CPK levels, particularly in patients on prolonged or high-dose therapy.